Business Wire

Western Union Highlights ESG Progress and Recognitions Received

Share

The Western Union Company (NYSE: WU) today released its 2021 Environmental, Social and Governance (ESG) Report, spotlighting the Company’s ongoing commitment to advancing its strategy and actions aligned with key ESG priorities.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005138/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Western Union's 2021 ESG report spotlights the Company’s ongoing commitment to advancing its strategy and actions aligned with key ESG priorities.(Photo: Business Wire)

“People are drawn to work for and do business with companies that make an impact,” said Devin McGranahan, Chief Executive Officer. “This year’s report shows that Western Union continues to make solid progress on our ESG journey, which in turn enables us to effect even more positive change in the communities we serve. I’m proud to work with colleagues who bring their best every day to improve the lives of our customers and communities around the world.”

2021 ESG Highlights

Western Union’s ESG strategy is focused on efforts and areas where the Company can make meaningful impact, including:

  • Furthering economic prosperity: The Company launched a digital banking platform in Germany and Romania, combining money transfer, a multi-currency account and debit card. Western Union believes offering people simple, trusted solutions via digital and retail access points creates pathways for long-term economic success.
  • Promoting the integrity of money movement: Western Union also continued progress on our commitment to money movement that is safe, secure and built on a foundation of integrity. While third-party data show the rate of fraudulent activity across the financial industry is increasing, in 2021 our Company’s reported consumer fraud globally decreased by 10% and we prevented approximately $1.9 billion in fraudulent transactions. These efforts were supported by fraud prevention messages that reached consumers through 121 million consumer fraud touches, a 97% increase over 2020.1
  • Advancing diversity, equity, and inclusion: Another key area of focus for the Company in 2021 was advancing diversity, equity and inclusion (DEI). In 2021, Western Union developed a DEI strategy focused on hiring, development, promotion, retention and cultural change. DEI milestones include:
    • A newly formed DEI program office, naming a Chief Diversity and Talent Officer, a specialized diversity recruiting lead and a full-time DEI program lead; and
    • Achieving gender pay equity globally and racial/ethnicity pay equity in the US.

This year also marks the first time Western Union has disclosed our Company’s Scope 1 and 2 greenhouse gas (GHG) emissions.

Increased Recognition

The Company also reported recognitions for its ESG efforts, including:

  • Recognized as one of the World’s Most Ethical Companies® for the first time;
  • Bloomberg’s Gender Equality Index for the third consecutive year;
  • JUST Capital’s Top 100 Companies Supporting Healthy Families and Communities; and
  • Human Rights Campaign’s Best Place to Work for LGBTQ+ Equality.

For more information and additional details related to our 2021 progress, and to download Western Union’s 2021 Environmental, Social and Governance (ESG) Report, click here.

About Western Union

The Western Union Company (NYSE: WU) is a global leader in cross-border, cross-currency money movement and payments. Western Union’s platform provides seamless cross-border flows and its leading global financial network bridges more than 200 countries and territories and over 130 currencies. We connect consumers, businesses, financial institutions, and governments through one of the world’s widest reaching networks, accessing billions of bank accounts, millions of digital wallets and cards, and a substantial global network of retail locations. Western Union connects the world to bring boundless possibilities within reach. For more information, visit www.westernunion.com.

________________________________

1. Consumer Fraud Awareness Touches are derived from metrics tracked across various platforms, including paid media ads, social media (Facebook, Twitter, YouTube, Community Management), outreach attendees and wu.com/fraudawareness visits. Each platform may have a unique method for quantifying individuals who have consumed anti-fraud content, based on reach, impressions, views, visits and/ or received physical materials. Given that consumers may engage with our content through multiple channels, each “touch” may not be a unique consumer.

WU-G

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Relations:
Claire Treacy
Claire.Treacy@westernunion.com

Investor Relations:
Tom Hadley
WesternUnion.IR@westernunion.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Unveils Nourish Innovation Lab in Union Beach, New Jersey19.8.2022 12:55:00 CEST | Press release

IFF (NYSE:IFF) today announced the opening of its new Nourish Innovation Lab at the company’s Union Beach, New Jersey research and development center. In the state-of-the-art lab, scientists—including flavorists and food designers—will leverage tools, technologies and ingredient expertise to offer customers full product design, driving growth in the global food and beverage markets by fast forwarding innovation. “This new facility is a testament to how we pioneer innovation and drive speed to market and accessibility to our customers,” said Nicolas Mirzayantz, president of Nourish, IFF. “We will nurture an innovation project from concept to kitchen table, under one roof. Using our scientific knowhow, application excellence and full portfolio of ingredients, we’ll improve the taste and nutrition profiles of next-generation food and beverages. With our new culinary kitchen, we’re enabling technology focused on the consumer-eating experience, taking food development out of the traditional

PUMA Ambassador and European Champion Gianmarco Tamberi Talks “Only See Great”19.8.2022 11:52:00 CEST | Press release

Six years after his first gold medal, Tamberi takes back the European title and speaks about his motivation to keep performing at the highest level in a video interview with sports company PUMA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220819005125/en/ Six years after his first gold medal, Tamberi takes back the European title and speaks about his motivation to keep performing at the highest level in a video interview with sports company PUMA. (Photo: Business Wire) With the ‘Only See Great’ campaign, PUMA explores the career path of its brand ambassadors, as they talk about their own pursuit of greatness, listening to their hearts, and finding a vision that no one else can see. In the interview, Gianmarco talks about his very first successes and extraordinary performance at the Olympic Games in Tokyo. “That feeling that I had that day, that happiness I couldn’t even imagine that could exist. It’s something that was co

Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)19.8.2022 10:30:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the European Commission (EC) approved CRYSVITA® (burosumab) for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed in the EU for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with fewer than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with progressive and debilitating musculoskeletal deficits,6,7 ultimately having a detr

Kapruvia ® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 07:00:00 CEST | Press release

Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a

European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer19.8.2022 04:47:00 CEST | Press release

Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer. “The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin®, Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.” The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom